Page last updated: 2024-11-04

n(1)-methylnicotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(1)-methylnicotinamide: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID457
CHEMBL ID1209652
CHEMBL ID71733
CHEBI ID16797
SCHEMBL ID132244
MeSH IDM0081959

Synonyms (47)

Synonym
CHEMBL1209652 ,
3-carbamoyl-1-methylpyridinium
trigonellinamide
1-methylnicotinamide cation
CHEBI:16797 ,
3-(aminocarbonyl)-1-methylpyridinium
pyridinium, 3-(aminocarbonyl)-1-methyl-
n(sup 1)-methylnicotinamide
1-methyl nicotinamide
brn 3540351
pyridinium, 3-carbamoyl-1-methyl-
1-methylpyridin-1-ium-3-carboxamide
n1-methylnicotinamide
1-methyl-3-carbamoylpyridinium
1-methylnicotinamide
3106-60-3
C02918
n(1)-methylnicotinamide
trigonellamide
1-mna
CHEMBL71733
BMSE000639
AKOS002665048
1-methylpyridine-3-carboxamide
unii-um47085bxc
um47085bxc ,
5-22-02-00145 (beilstein handbook reference)
bdbm50416500
n'methylnicotinamide
3-carbamoyl-1-methylpyridin-1-ium
gtpl4658
SCHEMBL132244
1-methylnicotinamide, n(1)-methylnicotinamide, 3-carbamoyl-1-methylpyridinium, n1-methylnicotinamide
FT-0696888
DTXSID10185019
8gc ,
n-1-methylnicotinamide
n-methyl-3-carbamidopyridinium
n-methyl-3-carbamoylpyridinium ion
3-carbamoyl-1-methyl-pyridinium
3-amido-n-methylpyridinium: 1-methyl-3-pyridinecarboxamide
i-methyl nicotinamide
1-methyl-3-carbamoylpyridinium cation
DB11710
Q27088080
NCGC00507724-01
1-methyl-nicotinsaeureamid

Research Excerpts

Overview

N1-Methylnicotinamide is an endogenous cationic metabolite of nicotinamide. Its renal clearance reflects both the capacity of the renal tubular transport system to secrete organic cations and renal plasma flow.

ExcerptReferenceRelevance
"N1-Methylnicotinamide (NMN) is an endogenous cationic metabolite of nicotinamide (niacine, vitamine PP) whose renal clearance reflects both the capacity of the renal tubular transport system to secrete organic cations and renal plasma flow. "( Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow.
Bélaz, N; Biollaz, J; Decosterd, LA; Kesselring, UW; Musfeld, C, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
"Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3
" The peak plasma concentration was achieved at 1 h in only 54% of the pharmacokinetic profiles, but at this time 92% of the profiles had already exceeded the target concentration of 700 nmol/ml, the level required in the mouse for tumour radiosensitization."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
"These data on the metformin-trimethoprim interaction support the potential utility of N(1)-methylnicotinamide as an endogenous probe for renal drug-drug interactions with involvement of renal cation transporters."( N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Auge, D; Fromm, MF; Hoier, E; Maas, R; Mieth, M; Müller, F; Pontones, CA; Renner, B; Zolk, O, 2015
)
2.08

Bioavailability

ExcerptReferenceRelevance
" Accordingly, it is suitable for quality-control applications, drug monitoring, and bioavailability and bioequivalency studies."( Spectrofluorimetric determination of warfarin sodium by using N1-methylnicotinamide chloride as a fluorigenic agent.
El Barbary, RA; El Dawy, MA; Mabrouk, MM,
)
0.13
" The proposed method is simple, with low instrumentation requirements, suitable for quality control application, bioavailability and bioequivalency studies."( Spectrofluorimetric determination of drugs containing active methylene group using N1-methyl nicotinamide chloride as a fluorigenic agent.
El Barbary, RA; El Dawya, MA; Mabrouk, MM, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves for AZT and probenecid, an organic anion inhibitor, revealed IC50 values of 225 and 15 microM, respectively."( Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles.
Griffiths, DA; Hall, SD; Sokol, PP, 1991
)
0.28
" Nor did their 14CO2 production differ after intraperitoneal dosing with [methylene-14C]tryptophan."( Leucine excess and niacin status in rats.
Carpenter, KJ; Cook, NE, 1987
)
0.27
" A dose-response curve for MPTP and its oxidized metabolite, MPP+, revealed IC50 values of 160 and 16 microM, respectively."( The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles.
Holohan, PD; Ross, CR; Sokol, PP, 1987
)
0.27
"Comparisons were made of the dose-response and time-course characteristics of nicotinamide (NIC) and its metabolite, N1-methylnicotinamide (MNIC), protection from alloxan-induced diabetes in mice."( Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice.
Falany, J; Fischer, LJ; Fisher, R, 1983
)
0.27
" At the same dosage (2 g/kg), in comparison with nicotinamide, nicotinic acid was weaker in raising plasma N(1)-methylnicotinamide levels (0."( Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats.
Cao, Y; Li, D; Li, SZ; Luo, N; Ma, Q; Shi, Q; Zhou, SS, 2013
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyridinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (13)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)1135
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Nicotinamide salvaging1030
Nicotinate and Nicotinamide Metabolism1434
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Folic acid network070

Bioassays (3)

Assay IDTitleYearJournalArticle
AID61001The maximal DA release induced by perfusion with 10 mM MPP+ (15 min) 1 day after perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID61002The maximum dopamine release induced by perfusion with the test compound with basal striatal DA (%of basal x10E-3)1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
In vivo intracerebral microdialysis studies in rats of MPP+ analogues and related charged species.
AID1445037Inhibition of recombinant human NNMT triple mutant expressed in Escherichia coli BL21/DE3 cells using quinoline as substrate assessed as decrease in formation of 1-MQ in presence of SAM by fluorescence assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (229)

TimeframeStudies, This Drug (%)All Drugs %
pre-199092 (40.17)18.7374
1990's38 (16.59)18.2507
2000's23 (10.04)29.6817
2010's57 (24.89)24.3611
2020's19 (8.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.29 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.18%)5.53%
Reviews10 (3.92%)6.00%
Case Studies1 (0.39%)4.05%
Observational0 (0.00%)0.25%
Other241 (94.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]